CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma by Kleinmanns, K. et al.
EBioMedicine 56 (2020) 102782
Contents lists available at ScienceDirect
EBioMedicine
journal homepage: www.elsevier.com/locate/ebiomResearch paperCD24-targeted fluorescence imaging in patient-derived xenograft models
of high-grade serous ovarian carcinomaKatrin Kleinmannsa,1, Katharina Bischofa,b,1, Shamundeeswari Anandana,b, Mihaela Popaa,c,
Lars A. Akslend, Vibeke Fossea,e, Ida Tveit Karlsena, Bjørn T. Gjertsena,f, Line Bjørgea,b,
Emmet McCormacka,*
a Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway
b Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021, Bergen, Norway
c KinN Therapeutics, Jonas Lies vei 91B, 5021, Bergen, Norway
d Centre for Cancer Biomarkers, CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Jonas Lies vei 87, 5020, Bergen, Norway
eDepartment of Radiology, Erasmus Medical Centre, 3000 CA Rotterdam, the Netherlands
f Department of Internal Medicine, Hematology Section, Haukeland University Hospital, 5021, Bergen, NorwayA R T I C L E I N F O
Article History:
Received 30 October 2019
Revised 2 April 2020
Accepted 21 April 2020
Available online 23 May 2020* Corresponding author.
E-mail address: emmet.mc.cormack@uib.no (E. McCo
1 These authors contributed equally to this work.
https://doi.org/10.1016/j.ebiom.2020.102782
2352-3964/© 2020 The Authors. Published by Elsevier B.A B S T R A C T
Background: The survival rate of patients with advanced high-grade serous ovarian carcinoma (HGSOC)
remains disappointing. Clinically translatable orthotopic cell line xenograft models and patient-derived xen-
ografts (PDXs) may aid the implementation of more personalised treatment approaches. Although orthotopic
PDX reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their
use in therapeutic development is limited by lack of appropriate imaging modalities.
Methods: We developed novel orthotopic xenograft and PDX models for HGSOC, and applied a near-infrared
fluorescently labelled monoclonal antibody targeting the cell surface antigen CD24 for non-invasive molecu-
lar imaging of epithelial ovarian cancer. CD24-Alexa Fluor 680 fluorescence imaging was compared to biolu-
minescence imaging in three orthotopic cell line xenograft models of ovarian cancer (OV-90luc+, Skov-3luc+
and Caov-3luc+, n = 3 per model). The application of fluorescence imaging to assess treatment efficacy was
performed in carboplatin-paclitaxel treated orthotopic OV-90 xenografts (n = 10), before the probe was eval-
uated to detect disease progression in heterogenous PDX models (n = 7).
Findings: Application of the near-infrared probe, CD24-AF680, enabled both spatio-temporal visualisation of
tumour development, and longitudinal therapy monitoring of orthotopic xenografts. Notably, CD24-AF680
facilitated imaging of multiple PDX models representing different histological subtypes of the disease.
Interpretation: The combined implementation of CD24-AF680 and orthotopic PDX models creates a state-of-
the-art preclinical platform which will impact the identification and validation of new targeted therapies,
fluorescence image-guided surgery, and ultimately the outcome for HGSOC patients.
Funding: This study was supported by the H2020 program MSCA-ITN [675743], Helse Vest RHF, and Helse
Bergen HF [911809, 911852, 912171, 240222, HV1269], as well as by The Norwegian Cancer Society
[182735], and The Research Council of Norway through its Centers of excellence funding scheme [223250,
262652].
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
Optical imaging
Fluorescence imaging
HGSOC
PDX
Biomarker
High-grade serous ovarian cancer
CD24rmack).
V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Epithelial ovarian carcinoma (EOC) remains the deadliest of all
gynaecological malignancies in developed countries, with high-grade
serous ovarian carcinoma (HGSOC) being the most common subtype
[1]. The five-year survival rate is still below 50%, primarily attributedto late stage diagnosis and chemoresistance [2]. Cytoreductive sur-
gery represents the main therapeutic option for the majority of
patients, and complete tumour resection is a critical prognostic
parameter for disease outcome [3,4]. Additional treatment
approaches for HGSOC include platinum-based chemotherapy, and
increasingly, precision therapeutics (e.g. VEGF- and PARP-inhibitors)
targeting biological characteristics of the tumour, such as angiogene-
sis and defective homologous recombination DNA repair [5]. These
novel classes of targeted drugs are fuelling hope of favourably chang-
ing the poor outcome for EOC patients [6,7]. The exploitation of
Research in Context
Evidence before this study
Patient-derived xenograft (PDX) models, incorporating inter-
patient and intra-tumour heterogeneity, are considered clini-
cally relevant animal models in prediction of patient outcome,
drug response and treatment efficacy. However, preclinical
PDX studies predominately employ subcutaneous engrafted
tumour models for exploring therapeutic concepts, which has
limited translational relevance. Orthotopic implantation of pri-
mary material into the physiological environment of the
murine ovary permits metastatic spread and formation of
malignant ascitic fluid, better reflecting the patient’s disease
course and clinical characteristics. Despite their superior clini-
cal relevance, a major limitation in application and translation
of preclinical concepts derived from orthotopic PDX models lies
in disease staging and subsequent determination of interven-
tion point. Thus, true exploitation of the translational power of
orthotopic PDX models demands development of relevant
imaging methodologies to quantify disease progression and
therapeutic efficacy.
Added value of this study
In this study, we have developed novel orthotopic epithelial
ovarian cancer patient-derived xenograft models, which
reflects clinical disease progression and dissemination. To over-
come the limited ability to monitor disease progression in these
models, we have developed a non-invasive imaging approach
using the EOC tumour-specific biomarker CD24. We demon-
strate that CD24-targeted near-infrared fluorescence imaging
allows visualisation of disease progression, identification of dis-
tant metastasis and the evaluation of treatment efficacy in
orthotopic cell line and clinically relevant PDX models. There-
fore, the presented methodology provides a new tool for pre-
clinical evaluation of disease progression, development of new
therapeutic regimes and precision therapy in the most clinically
relevant modelling system of HGSOC, namely PDX.
Implications of all the available evidence
Our study demonstrates that CD24-targeted near-infrared fluo-
rescence imaging of orthotopic PDX models of ovarian cancer
can aid the development and evaluation of novel therapeutic
drugs for ovarian cancer patients. PDX biobanks and the ability
to monitor disease progression in heterogenous models with
non-invasive imaging may further aid personalised medicine
allowing the examination of a variety of drugs, identifying the
most potent for each individual patient. CD24, a cancer stem
cell marker, involved in tumour metastasis, represents a bio-
marker, which is highly expressed not only in ovarian carci-
noma but also on several other tumours, and low in healthy
tissue. This emphasises CD24 not only as a biomarker for optical
near-infrared imaging in preclinical models but also a target for
therapeutic approaches, as well as a potential biomarker for
image-guided surgery.
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invasive imaging modality to detect tumour progression and
response to treatment. Imaging biomarkers VEGF and HER2 [8,9],
FRa [10], Thomsen-Friedenreich glycan antigen [11] and EpCAM [12]
for the detection of metastasised carcinomas have all shown poten-
tial in preclinical xenograft drug efficiency studies, as targeted thera-
peutics and potential targets to improve surgical resections in the
intraoperative setting [13,14].Development and exploitation of novel tumour-specific theranos-
tic biomarkers necessitates predictive preclinical models facilitating
clinical translation. Ideally, preclinical systems should model cancer
evolution as an interplay between neoplastically transformed,
immortalised cells and the surrounding and systemic environment
[15,16]. Genetically engineered models would initially appear ideal;
however, these models lack the disease heterogeneity observed clini-
cally while mouse homologues of human biomarkers often lack
cross-reactivity [17,18]. Thus, human xenograft models better satisfy
the conditions required for clinical translation of human imaging bio-
markers [19]. However, recent landmark papers have revealed that
commonly used HGSOC cell lines are not fully representative of the
human paradigm, many of which have lost key molecular traits of
the original samples [20,21]. Coupled with the frequent xenografting
of these cell lines subcutaneously or intraperitoneally - neither of
which replicates clinical conditions - necessitates more relevant
models to improve clinical translation. Patient-derived xenografts
(PDXs) represent a step towards optimal disease modelling as they
are known to preserve the genetic landscape, phenotypic traits,
including intra-tumour heterogeneity, and to predict response to
therapy of the primary patient sample [22-25]. As such, orthotopic
implantation of patient-derived material into immunocompromised
mice appears to offer the most relevant context for therapy develop-
ment in HGSOC [26,27], whilst also facilitating monitoring of tumour
progression and treatment response in preclinical drug efficacy stud-
ies [28].
Typically, preclinical imaging to monitor the spatio-temporal
development of disease, or therapeutic effects of novel agents in vivo,
relies heavily on bioluminescence imaging (BLI) and/or PET/CT
[29,30]. Nevertheless, BLI requires genetic alteration of the human
cells to facilitate reporter gene expression, in addition to selection or
sorting of expressing cells [30-32]. In the context of imaging PDX
models, application of reporter gene strategies may be detrimental to
the complex genetic traits and clonal heterogeneities prevalent in
primary patient material. Furthermore, the development of haemor-
rhagic ascites, typical in orthotopic HGSOC PDX, abrogates BLI
approaches owing to absorption of visible photons by haemoglobin,
while PET/CT strategies are expensive and low throughput [33,34].
Therefore, alternative approaches for non-invasive preclinical imag-
ing, particularly of orthotopic PDX models, are desired. Fluorescence
imaging (FLI) of ovarian PDX with application of exogenous near-
infrared (NIR) imaging probes thus appears a particularly attractive
concept, requiring no genetic manipulation, and potential clinical
translatability to PET/CT or fluorescence image-guided surgery (FIGS)
[35]. It has previously been demonstrated that the exploitation of
clinical immunophenotyping identified receptor-targeted optical
imaging probes, which could be employed in PDX imaging and subse-
quent therapeutic response [34,36].
The objective of this study was to elucidate novel imaging
markers for detection and monitoring of orthotopic HGSOC preclini-
cal models, in particular de novo heterogenous PDX models. Here, we
describe the identification of the EOC cell surface biomarker, CD24,
through screening of ovarian carcinoma cell lines and patient mate-
rial, and its application as an imaging biomarker. The choice of Alexa
Fluor 680 (AF680) as fluorescent conjugate for CD24 was based on its
spectral characteristics matching detector range of most optical
imaging systems. Furthermore, AF680 demonstrates superior quan-
tum yield and molecular extinction coefficients over corresponding
cyanine dyes and molecularly, contain less sulfonate groups resulting
in lower background accumulation [37,38]. We show that the conju-
gate of the monoclonal antibody CD24 and the NIR fluorophore
AF680 (CD24-AF680) have no effect on cell viability, and we demon-
strate that the application of this imaging probe for HGSOC cell line
xenografts leads to improved identification of intraperitoneal tumour
manifestations. Furthermore, the CD24-targeted NIR probe could be
used longitudinally to monitor disease progression and therapeutic
Table 1
Clinicopathological variables patients (n = 30).
Clinical parameters Total number of patients (n = 30)
Median (range)
Age at diagnosis (years) 66 (2883)
Follow-up time (months) 20 (162)
Progression-free interval (months) 16 (040)
Histological diagnosis N (%)
HGSOC 22 (73¢3)
Mucinous carcinoma of the ovary 1 (3¢3)
Clear cell carcinoma of the ovary 2 (6¢7)
Low-grade serous carcinoma of the ovary 2 (6¢7)
Endometroid carcinoma of the ovary 2 (6¢7)
Anaplastic carcinoma 1 (3¢3)
FIGO 2014 stage N (%)
IA 4 (13¢3)
IC 3 (10)
IIA 1 (3¢3)
IIB 4 (13¢3)
IIIA 1 (3¢3)
IIIC 13 (43¢3)
IV 4 (13¢3)
Level of surgical cytoreduction
Complete 16 (53¢3)
Residual disease at the end of surgery 14 (46¢7)
(Neo)adjuvant chemotherapy
Yes 7 (23¢3)
No 23 (76¢7)
Clinical characteristics (age at primary treatment, follow-up time and pro-
gression-free survival [PFS], histological subtype of epithelial ovarian carci-
noma, FIGO 2014 stage, level of complete cytoreduction during primary
surgery and chemotherapy status at time of sample collection) were col-
lected from tumour samples acquired from hysterectomy specimens or
diagnostic biopsies. PFS was defined as time in months from the first day of
primary treatment to disease recurrence.
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with low CD24 expression. Finally, we illustrate the application of
this probe in other CD24 expressing PDX models and postulate its
translational potential as an EOC theranostic.
2. Materials and methods
2.1. Cell lines and reagents
The human ovarian carcinoma cell lines Caov-3 (cat# HTB-75,
RRID: CVCL_0201), OV-90 (cat# CRL-11732, RRID: CVCL_3768), and
SKOV-3 (cat# HTB-77, RRID: CVCL_0532) were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA) and the
COV318 (cat# 07071903, RRID: CVCL_2419) cell line was purchased
through Sigma Aldrich (St. Louis, MI, USA). OV-90 cells were culti-
vated in RPMI 1640 and SKOV-3, Caov-3, and COV318 cells in Dulbec-
co’s modified Eagle’s medium (DMEM), supplemented with 10%
heat-inactivated foetal bovine serum and 2 mM L-glutamine at 37 °C
and 5% CO2.
2.2. Retroviral transduction of cell lines
We engineered clones that stably express the light-emitting
enzyme luciferase for the cell lines used, denoted Caov-3luc+, OV-
90luc+, SKOV-3luc+and COV318luc+. In order to achieve stable expres-
sion of luciferase, we used the construct L192 for the OV-90luc+, Caov-
3luc+ and SKOV-3luc+cell lines and the RediFect Red-FLuc-GFP lentivi-
ral particles (cat # CLS960003, Perkin Elmer, Inc., Waltham, MA, USA)
for COV318 both coding for the firefly luciferase enzyme. Infectious
viral particles were harvested after 24 h of incubation. Retroviral
infection was performed as described earlier [39] and according to
the manufactures protocol.
2.3. Flow cytometry analysis
Cells were detached from the culture flask using Trypsin (cat #
T3924-500, Sigma Aldrich), washed twice and a total of 5 £ 105 cells
of the Caov-3luc+, OV-90luc+, SKOV-3luc+, and COV318luc+ cell lines
were resuspended in 50 mL PBS (Dulbecco’s tablets, cat # P4417-
100TAB, Sigma Aldrich) supplemented with 1% solution of bovine
serum albumin (BSA) (cat # 05482100 G, Sigma Aldrich). Samples
were incubated on ice for 30 min with one of the following monoclo-
nal antibodies (mAb); EpCAM-PE (clone EBA-1, cat # 347198, RRID:
AB_400262, BD Biosciences, Franklin Lakes, NJ, USA), CD24-PE (clone
SN3, cat # LS-C46459-100, RRID: AB_1053866, LS Bio, Seattle, WA,
USA), CD44-PE (clone 7F1, cat # LS-C46494, RRID: AB_2074685, LS
Bio), FOLR1-PE (clone 548908, cat # FAB5646P, RRID: AB_10572835,
RD systems, Minneapolis, MN, USA), and TAG72-PE (clone B72.3, cat
# NBP2-52672PE, Novusbio, Littleton, CO, USA). Stained cells were
washed with 1% BSA/PBS and resuspended in PBS before cells were
acquired and recorded on a BD Accuri C6 or a BD Fortessa Flow
Cytometer (both BD Biosciences, Franklin Lakes, NJ, USA) in 3 repli-
cates.
2.4. Conjugation of antibody
A monoclonal, purified mouse-derived antibody directed against
CD24 (clone SN3, cat # MCA1379, RRID: AB_321526, Bio-Rad, Oxford-
shire, UK) was conjugated to the near-infrared dye Alexa Fluor 680
using the SAIVI Rapid Antibody Labelling Kit (cat # S30045, Invitrogen,
Carlsbad, CA, USA) and purified by size exclusion chromatography, as
described by the manufacturers. The resulting protein’s (CD24-AF680)
spectral characteristics were determined by Spark 20 M (Tecan,
M€annendorf, Switzerland, λabsorbance max 678 nm λfluorescence max
706 nm) and protein concentrations were determined with a Nano-
drop 1000 spectrophotometer (Fisher Scientific, Waltham, MA, USA).2.5. Cell viability and apoptosis assay of CD24-AF680 in vitro
Toxicity and proliferation of Caov-3luc+, OV-90luc+, SKOV-3luc+, and
COV318luc+ cells after incubation with CD24-AF680 were evaluated. To
validate the cell proliferation, cells incubated with CD24-AF680 and
controls without mAb were compared using the cell proliferation
reagent WST-1 (cat # 5015944001, Roche Applied Science, Pensberg,
Germany). According to the manufactures protocol, 2 £ 104 cells were
incubated for 24, 48 or 72 h with or without CD24 (4 mg; 0.04 mg/mL)
in triplicates before 10 ml of WST-1 reagent was added to the aliquots
(90 ml). The formazan concentration was measured after four hours
(Tecan Infinite 200 microplate reader and Magellan Version 6 Software;
Tecan Trading, Maennedorf, Switzerland). All samples were normalised
by the average of the 24-hour control triplet of each cell line. Apoptosis
was assessed by extracellular phosphatidyl serine staining combined
with propidium iodide (PI) (Alexa Fluor 488 annexin V/ Dead cell Apo-
ptosis Kit for Flow cytometry, cat # V13242, Thermofisher). The staining
was performed according to the manufacturers manual. In short,
1£ 105 cells of each cell line were cultured in a six wells-plate and incu-
bated for 24 or 48 h with CD24 mAb (4 mg). After incubation, control
and treated cells were detached from the culture plates with trypsin,
centrifuged and stained with 5 mL Alexa Fluor 488 Annexin V and 1 mL
100mg/mL PI in 60mL cell suspension for 15 min and analysed by flow
cytometry (BD LSR Fortessa).2.6. Patient characteristics and tissue processing
Tumour material was collected from a total of 30 women, who
were diagnosed with and treated for EOC at Haukeland University
Hospital, Bergen, Norway. Clinicopathological variables of the patient
cohort are listed in Table 1. The local ethics committee approved the
study and the biological samples were provided from the gynaeco-
logic Cancer Biobank, Womens Clinic, Haukeland University Hospital,
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informed consent was prospectively obtained from all women before
collection of fresh frozen tumour tissue and clinicopathological
parameters were initiated. After selecting non-necrotic tumour sam-
ples at a minimum size of 2 cm3, tissue was immediately processed.
Tumours were mechanically dissociated using two microscopic slides
until a homogenous cell suspension could be filtered through a
40 mm cell strainer (cat # 7322757, Corning Inc., USA). A part of the
patient samples was additionally treated with Collagenase II (300 U/
mL, cat # 17101015, Gibco, Paisley, UK) supplemented with the activ-
ity stabilizer CaCl2 and TrypLE (cat # 12604013, Gibco, Paisley, UK).
Cell suspensions were centrifuged at 350 g for five minutes, washed
twice with PBS and cell concentrations were determined using a hae-
matocytometer. Samples were stored in freezing medium (containing
a final 10% DMSO 90% FBS) in liquid nitrogen or immediately injected
into immunodeficient mice. Routine histopathological analysis of
implanted material was performed at the Haukeland University Hos-
pital, Department of Pathology, Bergen, Norway by experienced path-
ologists. Xenograft tissue specimens were fixed in buffered formalin
and further processed before histological sections (4 mm) were
made. Subsequently, slides were stained with Hematoxylin & Eosin
(H&E) for assessment of morphology and immunohistochemistry for
expression of CD24. Details of patients with corresponding engrafted
PDX are listed in Table 2.
2.7. In vivo xenograft models of ovarian cancer
Animal experiments were performed in accordance with the pro-
cedures from the Norwegian Commission for Laboratory Animals, the
European Convention for the Protection of Vertebrates Used forTable 2
CD24 expression profiles of patients included (n = 30).
Patient ID Tumour
engraftment
CD24 status CD24 SI
(continuous)
Histology
1 yes 1 4 HGSOC
2 yes 1 9 HGSOC
3 yes 1 9 HGSOC
4 yes 1 9 HGSOC
5 yes 1 6 HGSOC
6 yes 1 4 clear cell
7 yes 0 0 anaplastic
8 no 1 9 HGSOC
9 no 0 0 endometroid
10 no 1 3 endometroid
11 no 1 4 HGSOC
12 no 0 0 HGSOC
13 no 1 6 HGSOC
14 no 1 6 HGSOC
15 no 1 9 HGSOC
16 no 1 3 HGSOC
17 no 1 1 HGSOC
18 no 1 3 LGSOC
19 no 1 4 clear cell
20 no 1 6 HGSOC
21 no 1 2 HGSOC
22 no 1 6 HGSOC
23 no / / LGSOC
24 no 1 4 HGSOC
25 yes (P0) 1 4 HGSOC
26 no 1 4 HGSOC
27 no 1 9 HGSOC
28 yes (P0) 1 4 HGSOC
29 yes (P0) 1 4 HGSOC
30 yes (P0) 1 3 mucinous
Successful tumour engraftment yes (passage; P > 0, P = 0) or no; CD24 status
expressed as positive = 1 or negative = 0; SI = immunohistochemical staining
index calculated from CD24 staining intensity (03) x positive stained area
(03); 0 = no expression, 9 = strong expression; HGSOC = high-grade serous
ovarian carcinoma; LGSOC = low grade serous ovarian carcinoma.Scientific Purposes (EU Directive 2010/63/EU for animal experiments)
and the ethical standards given in the Declaration of Helsinki of 2008,
and approved by the Norwegian Food Safety Authority (Application
IDs 8066 and 14128). Six to eight-week-old female NOD-scid IL2rgnull
(NSG) mice (weight 22 - 28 g) were housed at the University of
Bergens animal facility under defined flora conditions in individually
ventilated (HEPA-filtered air) cages. No more than five mice were
housed in each individually ventilated cage, which was kept on a 12-
hour dark/night schedule at a constant temperature of 21 °C and at
50% relative humidity. Bedding and cages were autoclaved and
changed twice per month, and the mice were weighed twice weekly.
The animals had a continuous supply of sterile water and an irradi-
ated low auto-fluorescence rodent imaging diet (D1001, Research
diets, Brunswick, USA). Animals were monitored daily and sacrificed
following institutional guidelines, as defined by weight loss >10%, or
in case of ascites, distended abdomen, paleness, ruffled fur or leth-
argy. The post-mortem examination included macroscopic descrip-
tion of the primary tumour, presence and extent of metastases and
ascitic fluid. Organs were removed, and bioluminescence and fluores-
cence imaging were performed on explanted organs. Collected tissue
biopsies were fixed in 4% formaldehyde for 24 h, then washed in
ddH2O and transferred to 70% EtOH for long-term storage.
Ovarian carcinoma cell lines (OV-90luc+, SKOV-3luc+, and Caov-3luc+)
and patient-derived single cell suspensions, resuspended in PBS, were
xenografted either orthotopically or subcutaneously. Anaesthetic and
operative procedures for orthotopic xenograft models on mice were per-
formed as described previously [19]. For subcutaneous models, 5 £ 106
human tumour cells suspended in PBS were mixed 1:1 with Matrigel
membrane matrix (cat # 10365602, Corning Inc, USA) to a final volume
of 100 mL. Cell suspensions were injected bilaterally into the flanks of
female NSG mice after depilation and disinfection with chlorhexidine
5mg/mL (Fresenius Kabi, Halden, Norway).2.8. Optical imaging
Mice were fed a low auto-fluorescence rodent imaging diet
(cat # D1001, Research diets Inc., Brunswick, USA) for at least
one week prior to imaging experiments. The mice were anaesthe-
tised as described above and depilated before near infrared (NIR)
images were obtained with the Optix MX3 Small Animal Molecu-
lar Imaging system (ART Inc. Saint Laurent, QC, Canada) or the
IVIS Spectrum In Vivo Imaging System (Perkin Elmer). Fluores-
cence imaging (FLI) scans (MX3 λex = 670 nm, λem = 700 nm LP,
laser repetition rate 80 MHz, raster scan points 1 mm apart; IVIS
684 § 15 nm excitation bandpass filter and 702 § 10 nm emis-
sion bandpass filter) were obtained 24 h after administration (or
as otherwise indicated) of CD24-AF680 (total mAb concentration
of 2 mg/g body weight) [36]. The purified mouse IgG1 antibody
(cat # MCA928EL,RRID:AB_324,168, Bio-Rad) conjugated to Alexa
Fluor 680 was used as a negative control. For bioluminescence
imaging (BLI), bioluminescent signal was acquired 10 min after
the administration of D-luciferin (150 mg/kg, cat # L-8220, Bio-
synth, Staad, Switzerland). FLI and BLI of xenograft mice was per-
formed weekly. During early disease stages or minimal tumour
burden post-treatment, mice were imaged in the lateral view, to
allow for detection of small tumour deposits, whereas the ventral
view was used for visualisation of metastatic disease dissemina-
tion in the peritoneal cavity. All images and fluorescence lifetime
gating (Supplementary fig. S1) were analysed with OptiView soft-
ware (Version 2.02; ART Inc) and/or Living image software (Per-
kin Elmer) [40,41]. Background fluorescence signal, identified by
fluorescence lifetime gating (Supplementary fig. S1), was gated
out from all the resulting FLI images (OptiView software Version
2.02; ART Inc).
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xenograft models
NSG mice (n = 10) were implanted orthotopically with 2 £ 104
OV-90luc+ cells. Following the establishment of the primary tumour,
defined as the first FLI acquired signal at the primary injection site,
mice were randomised based on FLI signal intensity, and grouped
into two cohorts, vehicle control (n = 4) and treatment group (n = 6).
The treatment group received Paclitaxel (15 mg/kg; Fresenius Kabi,
Halden, Norway 6 mg/mL) and Carboplatin (12 mg/kg; Fresenius
Kabi, Halden, Norway 10 mg/mL) Q2Wx3. One day before the first
treatment and one week after the final treatment dose, all mice were
imaged laterally and ventrally by BLI and FLI as described above
(Optical imaging). All animals were sacrificed thereafter and disease
burden, tumour weights and ex vivo fluorescence intensities were
evaluated.
2.10. Intraoperative fluorescence imaging
The potential clinical application of CD24-AF680 as a tracer for
fluorescence image-guided surgery was investigated using the
FLARE intraoperative NIR fluorescence imaging system (Curadel
LLC, Marlborough, USA). Orthotopic OV-90luc+and one PDX model
were anaesthetised as described, and a midline coeliotomy was per-
formed. Intraoperative images were captured using the NIR 700
channel, λex = 665 § 3 nm and λem710 § 25 nm bandpass filters, at an
exposure time of 500 - 1500 ms and gain of 1. The colour video chan-
nel with an illumination source of 400 - 660 nm and the NIR 700
channel were simultaneously acquired and overlaid to a pseudo-col-
oured merge image in real-time. The imaging head was attached to
moveable arm, allowing a 245 cm working distance with a field of
view of 77 cm2. The mice were sacrificed at the end of the proce-
dure.
2.11. Histology and immunohistochemistry
Immunohistochemical (IHC) staining was done on formalin-fixed
and paraffin-embedded (FFPE) ovarian tumour tissues sectioned at
4 mm thickness. After de-paraffinization in xylene and rehydration
through graded ethanol series and distilled water solutions, the tis-
sues were subjected to heat-induced epitope retrieval undertaken in
TRS citrate buffer (pH=6.0) (cat # S1699, Agilent Technologies, Nor-
way) by the use of a microwave oven (Whirlpool, JT366; Expert
Bonus, Norway) for 20 min. After antigen retrieval, tissues were incu-
bated for 8 min with peroxidase blocker (Peroxidase Blocking
Reagent, cat #S2001, Agilent Technologies) and thereafter for 10 min
with protein blocker (Protein Block Serum-free, cat # X090930-2,
DAKO, Copenhagen, Denmark) at room temperature. The blocking
solution was then removed and the slide was wiped dry around the
tissue section before application of the primary antibody. The sec-
tions were then incubated overnight at 4C degrees with the CD24 pri-
mary antibody (clone SN3b, cat #MA5-11,833, RRID:AB_10,985,938
Thermo Fisher Scientific) dilution 1:25. The staining was performed
on a DAKO Autostainer using the EnVision+ System-HRP Labelled
Polymer Anti-Mouse K4001 as secondary antibody for 30 min (Agi-
lent Technologies, Norway). 3,3`-Diaminobenzine (DAB+) Substrate-
Chromogen was used as chromogen for 10 min. Sections were coun-
terstained with haematoxylin (cat # S3301, Agilent Technologies) for
10 min, dehydrated, and mounted with a coverslipper (Agilent Tech-
nologies) using Pertexx mounting medium (Histolab Products AB,
Askim, Sweden). Negative control sections underwent the same pro-
cedure but without including the primary antibody. Human tissue
from high-grade serous ovarian carcinoma with known reactivity to
the selected marker was used as positive control, and physiological
ovarian tissue from a healthy mouse of the same breed and age was
used as negative control. The CD24 staining indices for the patientsincluded are listed in Table 2. CD24 membrane expression by immu-
nohistochemistry was determined by a staining index (SI; range
09), representing the product of intensity (03; negative, weak,
moderate, strong; and area fraction of the tumour cells stained, 13;
1 = h10%; 2 = 1050%; 3 = i 50%). Cytoplasmic staining was observed
in some cases, also in benign tissues, but was not recorded.
2.12. Statistical methods
The association between categorical variables in patients, such as
CD24 expression status and tumour resectability or relapse status,
were evaluated using the Pearson Chi-square test. When correlating
non-binary variables, such as CD24 staining index, proliferation, apo-
ptosis, FIGO stage, histological subtype or fluorescence intensity,
with categorical variables for treatment outcome, the Mann-Whitney
U test was applied. Survival analyses were performed by the Kaplan-
Meier method, and subsets of patients were compared using the log-
rank test. All p-values are two tailed, and p-values < 005 were con-
sidered significant. Plot values are represented as mean § standard
deviation. Statistical analyses were performed using the software
package SPSS 24.0 (SPSS Inc., Chicago, IL, United States of America)
and GraphPad Prism (GraphPad Software Inc, San Diego, CA).
3. Results
3.1. Immunophenotyping of ovarian carcinoma cells and safety
evaluation of CD24 monoclonal antibody
We hypothesised that fluorescently labelled monoclonal antibod-
ies (mAbs), targeting highly expressed HGSOC antigens would allow
the specific non-invasive detection of ovarian cancer xenografts in
vivo. We screened a panel of EOC cell lines (OV-90luc+, Caov-3luc+,
SKOV-3luc+, and COV318luc+) for expression of putative biomarkers
(human-CD24, EpCAM, FolR1, CD44, and TAG72) by flow cytometry
(Fig. 1a) and identified CD24 as overall homogeneously, highly
expressed cell surface marker. CD24 expression was additionally
evaluated by IHC in a cohort of tumour samples from 30 patients
with EOC, of which almost 90% (26) stained positive for CD24, 10% (3)
were negative, and one patient could not be analysed (Table 2). To
determine whether the mouse anti-human CD24 mAb would have
any effect on cell proliferation or viability, all cell lines were incu-
bated with hu-CD24 for 24 to 72 h and proliferation assayed by WST-
1 and viability by Annexin V/PI assay (Fig. 1b and 1c). No significant
effects upon cell proliferation (Fig. 1b; p > 005) or cell viability
(Fig. 1c; p > 005) were noted.
3.2. In vivo CD24-AF680 identifies tumour lesions in epithelial ovarian
carcinoma cell line xenografts
To assess the sensitivity and specificity of CD24 as tumour-specific
target in vivo, the NIR fluorophore AF680 was conjugated to the
mouse anti-human CD24 mAb (as described in materials and meth-
ods). The biodistribution of CD24-AF680 and IgG1-AF680 was evalu-
ated in orthotopic xenograft models by dynamic imaging every 24 h
for five consecutive days (Supplementary fig. S2a). Non-invasive fluo-
rescence imaging indicated a long circulation time of CD24-AF680
with the highest signal intensity and tumour to background ratios
after 24 h similar to previous results with IgG conjugated mAbs (Sup-
plementary fig. S2a) [41-43]. To investigate CD24-specific accumula-
tion in tumour tissues, we compared the fluorescence intensity of
orthotopic tumours in xenograft models imaged with CD24-AF680
and IgG1-AF680 24 h after injection (Supplementary fig. S2b  S2e).
Ex vivo fluorescence imaging of dissected organs indicates the biodis-
tribution of the antibody-conjugate (Supplementary fig. 2b). Orthop-
tic and subcutaneous xenograft models imaged with CD24-AF680
revealed an increased fluorescence signal in the tumours compared
Fig. 1. Epithelial ovarian cancer biomarker screening and in vitro evaluation. (a) Flow cytometry-based analysis of stem cell marker expression profiles (CD24, EpCAM, FolR1, CD44
and Tag72) tested in three epithelial ovarian carcinoma cell lines (OV-90, Caov-3, and SKOV-3). The fluorescence staining index is based on the geometric mean fluorescence and
normalised to the unstained control. (p = 0026) The immunohistochemical staining index of CD24 (IHC, scale: negative 0  9 high) for all cell lines is indicated, correlating with the
fluorescence signal intensity (b) WST-1 cell proliferation assay; cells were incubated for 24, 48, and 72 h in triplicates with and without CD24 monoclonal antibody (mAb). Prolifera-
tion in all cell lines was quantified using the WST-1 reagent, normalised to 24 h control (p > 005). (c) After incubating the EOC cell cultures (n = 4) with and without CD24 mAb for
24 and 48 h, potential toxicity and side effects of the mAb were quantified using the Annexin V/PI staining assay (p> 005). Each column represents the mean with SD and statistical
analysis (Mann-Whitney U test) with p < 005 were regarded as statistically significant.
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assess the general in vivo application of CD24-AF680 for EOC imaging,
we employed the previously SKOV-3luc+ model [19], and generated
two orthotopic xenograft models of HGSOC using OV-90luc+ and
Caov-3luc+cell lines, described here briefly.
Single suspensions of luciferase expressing cells (5 £ 104 cells per
mouse) were orthotopically injected into the bursa of recipient NSG
mice (n = 5 per cell line) and mice were imaged weekly by BLI and FLI
(Fig. 2a, Supplementary fig. S3a, S4a). For the OV-90luc+ and SKOV-
3luc+ cell line models, a disease penetrance of 100% was observed,
while the Caov-3luc+ cell line formed tumours that could be visualised
by CD24-AF680 FLI and in ex vivo macroscopic examination in 40% of
animals. Mean survival times of 43 § 11 days (OV-90luc+),
79 § 20 days (SKOV-3luc+), and 227 days (Caov-3luc+) were noted for
the individual models. OV-90luc+ and SKOV-3luc+ models were charac-
terised by diffuse, intraperitoneal metastases after a minimum of
three weeks (Fig. 2a and 2b, Supplementary fig. S4), while only one ofthe Caov-3luc+implanted mice demonstrated metastatic spread (Sup-
plementary fig. S3).
Cumulative analysis and comparison of both FLI and BLI optical
imaging results from all three models (n = 3 mice per cell line) sug-
gest superiority of the CD24-AF680 protocol. While both BLI and FLI
permitted longitudinal monitoring of HGSOC disease dissemination,
CD24-AF680 FLI imaging permitted earlier tumour detection, most
evident in both Caov-3luc+ and SKOV-3luc+ models when compared
with BLI (Supplementary fig. S3 and S4). CD24-AF680 permitted visu-
alisation of superficial liver metastases in the OV-90luc+ model
(Fig. 2a and 2b), as well as allowing visualisation of bilateral ovarian
tumour masses in the Caov-3luc+ model, which were not evident in
corresponding BLI imaging, but confirmed to be malignant and CD24
positive by IHC (Supplementary fig. S3a). Thus, signal intensities of
fluorescence do not positively correlate with the total biolumines-
cence signal intensity (Fig. 2c). Similarly, evidence of metastases was
apparent from CD24-AF680 FLI imaging of the SKOV-3luc+ model as
Fig. 2. In vivo optical imaging of OV-90luc+xenograft models. (a) Comparison of longitudinal BLI and FLI imaging in orthotopic OV-90luc+xenograft models (n = 3). CD24-AF680 fluo-
rescence imaging, 24 h after probe injection, visualise the primary tumour and liver metastasis. (b) Ex vivo bioluminescence and fluorescence images demonstrate the tumour mani-
festation of one representative mouse. (c) Correlation of fluorescence to bioluminescence signal intensity measured in three individual mice over time (r2 = 014). (d) H&E stained
primary tumour tissue and abdominal metastasis and CD24 immunohistochemical staining of OV-90luc+tumour tissues (staining index = 4, scale: negative 0  9 high) and murine
ovarian tissue (negative); Scale bars: original magnification of x400 mm. All optical images are presented with the minimum to maximum fluorescence/bioluminescence intensity
for each mouse and ex vivo organs. FLI = fluorescence imaging; BLI = bioluminescence imaging; NC = number of counts; IHC = Immunohistochemistry.
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detection of metastases until four weeks later (Supplementary fig.
S4a). Ex vivo imaging confirmed that HGSOC tumour tissue was
detected with high specificity at both the primary injection site and
as disseminated disease, with superficial spread on the mesenteric
surface on the stomach, the intestine and the peritoneal lining of the
abdominal wall (Fig. 2a and b, and Supplementary fig. S4a and S4b).
The expression of the CD24 surface biomarker was confirmed on cell
line xenografts ex vivo by IHC (Fig. 2d). Analysis revealed that
tumours derived from implantation of OV-90luc+ and SKOV-3luc+
showed membranous CD24 expression with an immunohistochemi-
cal staining index (scale: negative = 0  9 = high) of four and two,
respectively (Fig. 2d, Supplementary fig. S4d). For implants derived
from xenografted Caov-3luc+cells, we confirmed the bilateral tumour
dissemination and identified low CD24 expression (staining index 1 -
2) in the primary tumour and uterus, thus supporting the specificity
of CD24-AF680 (Supplementary fig. S3d and S3e).3.3. CD24-AF680 enables reliable FLI monitoring of treatment efficacy
Given the observed sensitivity of CD24-AF680 for optical imaging
of EOC xenografts, we addressed the utility of CD24-AF680 in a thera-
peutic setting with the OV-90luc+xenograft model. OV-90luc+xeno-
grafted mice (n = 10) were imaged weekly and upon tumour
manifestation at the primary tumour site, as visualised by CD24-
AF680, were randomised according to fluorescence intensity into two
cohorts. One cohort was treated with a combination regime of
15 mg/kg paclitaxel and 12 mg/kg carboplatin twice weekly for 3
consecutive weeks, while the second served as vehicle control. CD24-
AF680 imaging was performed immediately prior to and post therapy
(Fig. 3a). Analysis of CD24-AF680 imaging of the control cohort (n = 4)
illustrated progressive disease stages with visible metastases noted at
distal sites such as the kidney, diaphragm, liver and stomach (Fig. 3a
and 3c). Quantification of CD24-AF680 fluorescence revealed an
almost 4-fold average increase in fluorescence intensity post-
Fig. 3. CD24-FLI application study in orthotopic OV-90luc+xenograft models. (a) Illustration of CD24-NIR fluorescence imaging in three representative OV-90luc+orthotopic xeno-
grafted mice before and after treatment with chemotherapy (12 mg/kg carboplatin and 15 mg/kg paclitaxel [Q2Wx3]) and control. Mice marked with “#” are represented with
higher maximum values. (b) The mean total fluorescence intensity before and after chemotherapy is illustrated for control and treated animals (n = 10, p = 00095). (c) Ex vivo fluo-
rescence images and necropsy pictures (scale bar 1 cm) presenting (*-marked) tumour infiltrated organs and tumour progression in control versus treated mice. (d) Correlation of
total fluorescence intensity and tumour load, represented as tumour weight (r2 = 067) in control and treated mice (p = 00038). Data points represented as mean and SD. Statistical
analysis (Mann-Whitney U test) with p < 005 (*), p < 001 (**) were regarded as statistically significant. FLI = fluorescence imaging; NC = number of counts; GI = gastrointestinal
tract.
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treatment 3748 £ 105 § 311 £ 105 [NC x 105]; p < 003). In con-
trast, CD24-AF680 imaging of the treated group revealed an average
decrease in total fluorescence post therapy (pre-treatment
1016 £ 105 § 44 £ 105 vs post-treatment 763 £ 105 § 53 £ 105
[NC x 105]) suggesting stable/reduced disease burden (Fig. 3B; p >
005). Comparison of CD24-AF680 FLI demonstrated therapeutic
effect, with significant differences in total fluorescence exhibited
between groups post-treatment (Fig. 3b; p < 001). All animals were
euthanised post therapy, examined macroscopically, imaged and
weighed. While ex vivo imaging confirmed the presence of metasta-
ses in the control cohort, both imaging and macroscopic examination
confirmed that the disease was confined to visible primary tumours
in the treated cohort (Fig. 3c). Finally, tumour weights of control and
treated primary tumours confirmed CD24-AF680 imagingobservations of significant differences following therapy (Fig. 3d;
71 § 52 mg vs2098 § 989 mg; p < 001, r2 = 067) thus demonstrat-
ing the utility of CD24-AF680 FLI to accurately determine therapeutic
effect non-invasively.
3.4. FLI of CD24-AF680 in patient-derived xenograft models
Having established the application of CD24-AF680 targeted FLI in
longitudinal and therapeutic imaging of EOC cell lines, we wished to
examine its utility for imaging heterogeneous PDX models of HGSOC
by fluorescence as an approach to circumvent the transduction of pri-
mary material. Samples from 30 individual patient tumour tissues
were collected at the time of primary surgery (patient characteristics
Tables 1-3). After immediate tissue processing, single cell suspen-
sions containing 1 £ 104 to 5 £ 104 patient-derived cells were
Table 3
Clinicopathological variables PDX models (n = 7).
Patient characteristics PDX characteristic CD24 status
PDX Age Histology FIGO PFS (months) Disease Latency (weeks) Patient (SI) PDX (SI)
1 52 HGSOC IV 9 11 4 9
2 38 HGSOC IIIC 40 19 9 9
3 75 HGSOC IIIC 9 61 6 6
4 42 HGSOC IIIC 13 16 9 4
5 64 HGSOC IIA 2 13 6 6
6 78 Clear cell IA 19 54 4 4
7 60 Anaplastic IIIC 1 9 0 2
Clinical characteristics: Patient age at primary treatment, histological subtype of epithelial ovarian carcinoma,
FIGO 2014 stage, progression-free survival (PFS), engraftment time in immunodeficient mice and CD24 expression
status of the original patient material and the corresponding PDX sample indicated as immunohistochemical
staining index (SI). SI = CD24 staining intensity (03) x positive stained area (03); 0 = no expression, 9 = strong
expression. PFS was defined as time in months from the first day of primary treatment to disease recurrence.
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subcutaneously into the flank of female NSG mice (n = 1 mouse per
patient sample). Tumour engraftment was confirmed in 11 of 30
samples (overall engraftment of 37%), with seven (consisting of five
HGSOC tumours, one anaplastic tumour, and one clear cell carci-
noma) developing reproducible disease models (23%; Fig. 4, Supple-
mentary fig. S5, Table 2 and 3). Time to engraftment was between 9
and 61 weeks and murine PDX development was associated with a
significantly shorter time to clinical progression in the patient (log-
rank test, p = 0003; see Supplementary fig. S6). In all seven (100%)
passaged PDX we confirmed CD24 expression by IHC and CD24
expression status was conserved in four of seven specimens (57%)
(Fig. 4d and 4e, Supplementary fig. S5, Table 3). Interestingly, CD24
staining index increased in the two PDX models with the shortest
overall engraftment time.
Initially, we examined the utility of CD24-AF680 FLI to visualise a
subcutaneous HGSOC PDXmodel, and we demonstrated both fluores-
cent staining of in vivo tumours and a strong correlation (r2 = 096)
between tumour volume and CD24-AF680 fluorescence intensity
(Fig. 4a). Next, we assessed CD24-AF680 FLI in orthotopic HGSOC
PDX models (Fig. 4b). CD24-AF680 FLI revealed orthotopic tumour
engraftment in the ovary and tumour dissemination in the peritoneal
cavity, the stomach and omental tissue (Fig. 4b and 4c). Ex vivo exam-
ination and CD24-AF680 imaging demonstrated that fluorescence
was detected in the ovaries and in peritoneal metastases, and meta-
static spread was identified in the contralateral ovary, the perito-
neum, liver, stomach, and diaphragm, similar to the disease
progression observed in the patient counterpart (Fig. 4c and 4e).
Human tumour origin and CD24 expression was confirmed in all
HGSOC PDX models by H&E and IHC (Fig. 4d). To evaluate the rele-
vance and sensitivity of CD24-AF680 FLI in longitudinal monitoring
of HGSOC disease progression, we imaged one PDX model over its
disease course, noting a linear increase in fluorescence over time
(Fig. 4e). The data suggest the high potential of CD24-AF680 targeted
FLI in all engrafted HGSOC PDXs with the ability to follow tumour
progression. To demonstrate the versatility of CD24-AF680 FLI in
imaging other CD24+ PDX models, CD24-AF680 FLI was employed to
visualise engraftment in a PDXmodel of clear cell carcinoma and ana-
plastic carcinoma (Supplementary fig. S5). Interestingly, while the
primary patient sample of PDX7 was confirmed to be CD24 negative
by IHC and of an anaplastic subtype, the PDX sample stained positive
for CD24 with a staining index of two and an overall short engraft-
ment time of nine weeks. While in vivo FLI imaging with CD24-AF680
of PDX7 revealed abdominal and liver metastases, primary in vivo
tumour fluorescence was absent, and only possible to demonstrate ex
vivo. This tumour was highly vascularised, suggesting that in vivo
fluorescence was absorbed by haemoglobin (Supplementary fig. S5b).
Given the recent developments of tumour-targeted fluorescence
image-guided surgery in ovarian cancer patients, there is a need fornovel tumour-specific biomarkers which are not widely expressed in
healthy tissues. Considering the applicability of CD24-AF680 for non-
invasive fluorescence imaging, we investigated whether the probe
also comprises potential for intraoperative image-guided surgery. In
one orthotopic OV-90luc+ and one PDX model (n = 2), CD24-AF680
facilitated real-time, intraoperative detection of the primary tumour
(Supplementary fig. S7a and S7b). In addition, ovarian metastatic
tumour lesions in the spleen were identified (Supplementary fig.
S7a). Autofluorescence from the stomach and gastrointestinal tract
were observed at this wavelength (Supplementary fig. S7, green
dashed lines).
4. Discussion
The cell surface marker CD24 has been shown to be significantly
upregulated in a number of carcinomas compared to their benign
counterparts, suggesting it as an ideal target for theranostic applica-
tions [44-46]. In our cohort of 30 cases of epithelial ovarian carci-
noma we found expression of CD24 present in 90% of tissues,
concurring with the observation that CD24 is highly expressed in the
vast majority of ovarian cancer cases [47-49] with highest expression
levels in the serous subtype [47,48,50,51]. Overdevest et al. reported
higher CD24 staining indices in metastases and identified CD24 as
the most overexpressed amongst transcripts in metastasising cells of
human bladder carcinoma [52]. Numerous studies have associated
CD24 expression on different tumour types with poor prognosis,
tumour aggressiveness and positive correlation of CD24 expression
to tumour growth, cell invasion and metastatic progression [45,51].
While we did not observe an association of CD24 expression with dis-
ease characteristics, resectability, FIGO stage or histological subtype
in our clinical cohort of 30 patients, all seven PDX models derived
from these samples demonstrated an aggressive clinical course,
which might be explained by our highly selected patient series,
which included clinically aggressive and mainly advanced tumours.
The results presented here may have broad applications for the
modelling, detection and targeted treatment of advanced HGSOC.
Translational and personalised therapy development is dependant on
the fidelity of preclinical models that faithfully recapitulate the clini-
cal paradigm [16]. Both the OV-90luc+ and Caov-3luc+ orthotopic mod-
els presented here are previously undescribed. These models
accurately reflect the morphological characteristics, typical diffuse
dissemination and ascites production throughout the peritoneal cav-
ity observed clinically in HGSOC. Several reports have independently
demonstrated that these cell lines result in greater molecular fidelity
to HGSOC compared with the most commonly used cell line SKOV-
3luc+and we additionally demonstrate the efficacy of the orthotopic
OV-90luc+ model in evaluation of clinical employed chemotherapeu-
tics [20,21,53,54]. Coupled with the establishment of a panel of seven
clinically annotated PDX models with patient FIGO stage II-IV, which
Fig. 4. Fluorescence imaging of high-grade serous ovarian cancer patient-derived xenograft (PDX) models using CD24-AF680. (a) Fluorescence imaging enables the detection of
tumour progression in subcutaneous PDX models. Linear regression analysis showed correlation (r2 = 096) of tumour size to fluorescence intensity. (b) Orthotopic implanted PDX
models (n = 4) were imaged 24 h after CD24-AF680 injection (2 mg/g). Primary tumour lesions and metastases were detected by fluorescence optical imaging in vivo and (c) ex vivo.
(d) Immunohistochemical (IHC) and H&E staining of the primary tumour and metastases confirmed CD24 expression and human tumour origin. Scale bars: original magnification
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tumour, these models provide a crucial platform for therapy develop-
ment in HGSOC. High throughput drug screening in genomically
characterised PDXs showed 95% congruency with clinical response in
several solid tumour types and is currently being evaluated in a phase
II clinical trial (NCT02312245) for EOC [26,55,56].
Bioluminescence imaging is considered the gold standard of opti-
cal imaging, requiring the integration of reporter gene DNA into the
chromosomes of the tumour cells [57]. This may inadvertently dis-
rupt the delicate genomic landscape of primary patient material, and
additionally becomes expensive in larger cohorts of PDX. In the cur-
rent study we demonstrate the usefulness of CD24-AF680 FLI
approach, particularly in early and metastatic detection in HGSOC
preclinical models and we showed the ability to longitudinally follow
disease progression in both cell line and PDX models using CD24-
AF680, avoiding unnecessary genetic alteration of the cell genome.
However, long circulation time of the monoclonal antibody suggests
the further development of the probe into antibody fragments, such
as nanobodies, diabodies or affibodies, with preferred biodistribution
characteristics that would allow more frequent imaging [58,59].
Attempts to enhance tumour to background ratios on the one hand,
and limited tissue penetration depth of fluorescence on the other, are
further exploited by the development of activatable probes, longer
wavelength shifted NIR I fluorophores (e.g. IRDye 800CW, ZW800-1)
and synthetic nanoprobes labelled with NIR II fluorophores [60-62].
A caveat of non-invasive optical approaches is the limited sensitivity
in highly vascularised and haemorrhagic environments, as demon-
strated for PDX7. Numerous studies have highlighted the potential of
CD24 as a therapeutic agent to reduce tumour growth, alter the intra-
tumoural cytokine microenvironment, increase the infiltration of
immune cells into the tumour tissue and investigate CD24 in adop-
tive immunotherapy [52,63,64]. Thus, evolution of our CD24-AF680
probe to incorporate a PET radionuclide such as 89Zr or 64Cu or SPECT
probe 68Ga or 111In would generate a quantitative theranostic probe
with immediate translational relevance and overcome the limited
penetration depth of fluorescence optical imaging [65]. Furthermore,
numerous studies have investigated the tumour-targeted approach
for fluorescence image-guided surgery (such as folate receptor a,
HER2, VEGF, osteonectin etc.), in addition to targeted drug delivery
with promising results [13,66-69]. Thus, it would be interesting to
further explore the application of CD24 conjugated to more NIR-
shifted fluorophores in real-time intraoperative identification to
improve the detection and surgical resection of malignant metastatic
lesions [14,70].
In conclusion, we have identified CD24 as an imaging biomarker
of HGSOC. Application of a monoclonal antibody targeting CD24
labelled with the near-infrared fluorophore Alexa Fluor 680 (CD24-
AF680) was demonstrated to functionally visualise the pathogenesis
of several preclinical models of HGSOC, including previously unde-
scribed HGSOC cell line xenograft models of OV-90luc+, Caov-3luc+,
and HGSOC PDXs (n = 7). CD24-AF680 neither affected cell viability in
vitro, nor disease dissemination in vivo. Comparative optical imaging
of cell line xenografts expressing bioluminescent reporters illustrated
that FLI of CD24-AF680 permitted earlier disease contrast in perito-
neal regions than BLI. CD24-AF680 could be used to image HGSOC
therapeutic efficacy of new targeted therapy and immunotherapy
combination strategies in orthotopic humanised HGSOC mice in vivo,
and engraftment in PDX models with low CD24 expression and other
peritoneally disseminating anaplastic cancers. Finally, CD24-AF680
allowed for real-time intraoperative identification of both the pri-
mary tumour and metastases in EOC xenografts. The findings demon-
strate the successful use of an antibody mediated fluorescenceof x400 mm (e) Monthly longitudinally fluorescence imaging illustrates linear increase in me
inal magnification of x400 mm) and ex vivo imaging (scale bar 1 cm) confirmed high CD24 ex
scale: negative 0  9 high). Images are presented with the minimum to maximum fluorescenimaging protocol of HGSOC PDX models that may be translatable as a
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